85826-33-1

Basic information

• Product Name: 5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE
• Synonyms: 5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE
• CAS NO: 85826-33-1
• Molecular Formula: C₈H₈Cl₂N₂
• Molecular Weight: 203.07
• Mol File: 85826-33-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 261°C at 760 mmHg
• Flash Point: 136.9°C
• Appearance: /
• Density: 1.265g/cm³
• Vapor Pressure: 0.0193mmHg at 25°C
• Refractive Index: 1.547
• CAS DataBase Reference: 5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE(85826-33-1)
• EPA Substance Registry System: 5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE(85826-33-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 85826-33-1(Hazardous Substances Data)

Usage

General Description

5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE is a chemical compound that belongs to the class of pyrimidine derivatives. It is characterized by the presence of an allyl group, two chlorine atoms, and a methyl group attached to a pyrimidine ring. 5-ALLYL-4,6-DICHLORO-2-METHYLPYRIMIDINE has potential applications in the field of organic chemistry and pharmaceuticals due to its unique structure and reactivity. It may be used as a building block in the synthesis of various organic compounds, or it could potentially exhibit biological activity that makes it useful for drug development. Overall, this chemical compound has diverse potential applications and is of interest to researchers in various fields.

InChI:InChI=1/C8H8Cl2N2/c1-3-4-6-7(9)11-5(2)12-8(6)10/h3H,1,4H2,2H3

Upstream product

• 85826-32-0 5-Allyl-2-methyl-4,6-dihydroxypyrimidine 
• 2049-80-1 (2-propenyl)propanedioic acid diethyl ester 
• 124-42-5 acetamidine hydrochloride 
• 85826-32-0 6-hydroxy-2-methyl-5-(2-proren-1-yl)-4(1H)-pyrimidinone 

Downstream Products

• 85826-34-2 5-Allyl-4-amino-2-methyl-6-chloropyrimidine 
• 1001397-48-3 6-chloro-N-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-5-(2-propen-1-yl)-4-pyrimidinamine 
• 1001397-56-3 1-methylethyl 4-({7-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate 
• 1001397-53-0 1,1-dimethylethyl 4-({7-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate 
• 1001397-52-9 4-chloro-7-[2-fluoro-4-(methylsulfonyl)phenyl]-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 
• 85826-41-1 Benzyl-[6-chloro-5-(2,3-dibromo-propyl)-2-methyl-pyrimidin-4-yl]-amine 
• 85826-40-0 2-[6-Chloro-5-(2,3-dibromo-propyl)-2-methyl-pyrimidin-4-ylamino]-ethanol 
• 85826-39-7 [6-Chloro-5-(2,3-dibromo-propyl)-2-methyl-pyrimidin-4-yl]-methyl-amine 
• 85826-38-6 4-Amino-5-(2',3'-dibromo-1'-propyl)-2-methyl-6-chloropyrimidine 
• 644994-58-1 allyl-[5-bromo-7-(2,4-dichloro-phenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-cyclohexyl-amine 
• 268547-66-6 N-Allyl-3-bromo-1-(2,4-dichlorophenyl)-4-(4-heptyl)amino-6-methyl-5,7-diazaindole 
• 268547-65-5 3-Bromo-1-(2,4-dichlorophenyl)-4-(4-heptylamino)-6-methyl-5,7-diazaindole 
• 644994-57-0 allyl-[5-bromo-7-(2,4-dichloro-phenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-methyl-amine 
• 644994-55-8 5-bromo-4-chloro-7-(2,4-dichloro-phenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available g protein-coupled receptor 119 agonists

GPR119 is a 7-transmembrane receptor that is expressed in the enteroendocrine cells in the intestine and in the islets of Langerhans in the pancreas. Indolines and 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines were discovered as G protein-coupled receptor 119

CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS

The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof (Formula (I)) wherein the dashed line may represent a double bond; R is aryl or heteroaryl, each of which m

CRF receptor antagonists and methods relating thereto

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, m, A, B, C, R, R1, R2and Ar are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same